Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 30, 2022 at 03:56 am IST
Share
Lionco Pharmaceutical Group Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 126 million compared to CNY 273.97 million a year ago. Revenue was CNY 126 million compared to CNY 273.97 million a year ago. Net income was CNY 20.56 million compared to CNY 35.11 million a year ago. Basic earnings per share from continuing operations was CNY 0.03 compared to CNY 0.05 a year ago. Diluted earnings per share from continuing operations was CNY 0.03 compared to CNY 0.05 a year ago.
Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.